| 1 |
34312098 | Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients. | 2022 Jan |
2 |
| 2 |
34655345 | Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysis. | 2022 Jan |
1 |
| 3 |
34758639 | Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience. | 2022 Jan |
1 |
| 4 |
34773540 | Experimental and computational assessment of the synergistic pharmacodynamic drug-drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells. | 2022 Apr |
1 |
| 5 |
35015188 | Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). | 2022 May |
4 |
| 6 |
35083840 | Targeted Nanoparticle for Co-delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis. | 2022 Mar |
2 |
| 7 |
35242683 | Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial. | 2022 Jan |
2 |
| 8 |
35405088 | De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. | 2022 May |
1 |
| 9 |
35531104 | Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin, and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial. | 2022 Apr |
1 |
| 10 |
35534752 | Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women. | 2022 Jul |
1 |
| 11 |
32715420 | Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. | 2021 Jan |
1 |
| 12 |
33024896 | Conferring receptors on recipient cells with extracellular vesicles for targeted drug delivery. | 2021 Mar |
2 |
| 13 |
33319669 | Resistance to Intervention: Paclitaxel in Breast Cancer. | 2021 |
1 |
| 14 |
33393480 | Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis. | 2021 Jan |
2 |
| 15 |
33585999 | Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. | 2021 May |
1 |
| 16 |
33587352 | Nuclear Her2 contributes to paclitaxel resistance in breast cancer cells. | 2021 Aug 1 |
14 |
| 17 |
33597376 | [A Case of HER2-Positive Metastatic Breast Cancer Achieved a Complete Response to Paclitaxel and Trastuzumab in Combination with Pertuzumab in Fifth Therapy]. | 2021 Feb |
2 |
| 18 |
33602685 | Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. | 2021 Jul 15 |
1 |
| 19 |
33737682 | Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer. | 2021 Mar 18 |
2 |
| 20 |
33809310 | [89Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models. | 2021 Mar 12 |
4 |
| 21 |
33996222 | Anti-HER2 PLGA-PEG polymer nanoparticle containing gold nanorods and paclitaxel for laser-activated breast cancer detection and therapy. | 2021 Apr 1 |
1 |
| 22 |
34064007 | Nature-Inspired Nanoparticles as Paclitaxel Targeted Carrier for the Treatment of HER2-Positive Breast Cancer. | 2021 May 21 |
1 |
| 23 |
34126209 | Lapatinib enhances paclitaxel toxicity in MCF-7, T47D, and MDA-MB-321 breast cancer cells. | 2021 Sep |
1 |
| 24 |
34256895 | Identifying prognostic factors associated with overall survival in second-line paclitaxel plus ramucirumab treated human epidermal growth factor receptor 2-negative advanced/recurrent gastric cancer. | 2021 Jul 1 |
2 |
| 25 |
34268990 | Sequential anthracycline and weekly paclitaxel might be more effective compared to docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients. | 2021 May-Jun |
1 |
| 26 |
34320531 | HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas. | 2021 Jul 28 |
2 |
| 27 |
34404077 | [A Case of Pseudopancreatic Cyst Development during Bevacizumab plus Paclitaxel Therapy for Pancreatic Metastasis of Breast Cancer]. | 2021 Aug |
1 |
| 28 |
34567947 | Potential effectiveness of combining bevacizumab with paclitaxel for treating HER2-positive metastatic breast cancer. | 2021 Oct |
4 |
| 29 |
34590151 | CMBs carrying PTX and CRISPR/Cas9 targeting C‑erbB‑2 plasmids interfere with endometrial cancer cells. | 2021 Dec |
1 |
| 30 |
34695904 | [Multi-center real world study of the efficacy and safety of albumin-bound paclitaxel in the treatment of advanced breast cancer]. | 2021 Oct 23 |
2 |
| 31 |
34778301 | Preclinical Assessment of Paclitaxel- and Trastuzumab-Delivering Magnetic Nanoparticles Fe3O4 for Treatment and Imaging of HER2-Positive Breast Cancer. | 2021 |
1 |
| 32 |
34781168 | TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. | 2021 Dec |
2 |
| 33 |
34917174 | Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial. | 2021 |
2 |
| 34 |
31633500 | Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models. | 2020 Mar |
1 |
| 35 |
31873051 | Herceptin-decorated paclitaxel-loaded poly(lactide-co-glycolide) nanobubbles: ultrasound-facilitated release and targeted accumulation in breast cancers. | 2020 Apr |
2 |
| 36 |
31899273 | Multivalent HER2-binding polymer conjugates facilitate rapid endocytosis and enhance intracellular drug delivery. | 2020 Mar 10 |
1 |
| 37 |
31969184 | Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer. | 2020 Jan 22 |
1 |
| 38 |
32187596 | Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer. | 2020 |
1 |
| 39 |
32239987 | Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer. | 2020 Mar |
1 |
| 40 |
32259780 | Undetectable Tumor Cell-Free DNA in a Patient With Metastatic Breast Cancer With Complete Response and Long-Term Remission. | 2020 Apr |
1 |
| 41 |
32273207 | Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO. | 2020 Jun |
1 |
| 42 |
32461977 | Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study. | 2020 |
1 |
| 43 |
32501121 | Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients. | 2020 Aug |
1 |
| 44 |
32574131 | Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities. | 2020 Nov |
1 |
| 45 |
32611325 | Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review. | 2020 Jul 1 |
1 |
| 46 |
32706146 | Experiences of trastuzumab plus paclitaxel combination therapy in metastatic human epidermal growth factor receptor 2-positive extramammary Paget's disease: Four cases and a review. | 2020 Nov |
2 |
| 47 |
32776291 | Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer. | 2020 Nov |
3 |
| 48 |
32843422 | Paraneoplastic cerebellar degeneration diagnosed by anti-Yo determination in a young woman with early breast cancer. | 2020 Aug 24 |
1 |
| 49 |
32959525 | Programmable Delivery of Synergistic Cancer Drug Combinations Using Bicompartmental Nanoparticles. | 2020 Nov |
1 |
| 50 |
32998859 | Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva. | 2020 Nov |
1 |